FRA
GTBP icon

Front Row Advisors’s GT Biopharma GTBP Stock Holding History

Front Row Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$4 – 556
2025
Q2 		$4 Hold
1
– – ﹤0.01% 534
2025
Q1 		$2 Buy
+1
New +$2 ﹤0.01% 510
2024
Q3 		– Sell
-1
Closed -$3 – 647
2024
Q2 		$3 Hold
1
– – ﹤0.01% 941
2024
Q1 		$4 Sell
1
-1
-50% -$5 ﹤0.01% 927
2023
Q4 		$15 Hold
2
– – ﹤0.01% 470
2023
Q3 		$14 Hold
2
– – ﹤0.01% 917
2023
Q2 		$0 Hold
2
– – ﹤0.01% 912
2023
Q1 		$0 Buy
+2
New +$46 ﹤0.01% 923

Other funds holding GTBP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Front Row Advisors's GTBP Position: Q3 2025 in Review

Front Row Advisors sold out of GT Biopharma (GTBP) in Q3 2025, closing a stake of 1 share — an estimated $4 sold.

Front Row Advisors first reported a position in GTBP in Q1 2023 and held it in 8 quarters. The position peaked at $15 in Q4 2023. 21 funds tracked by Wall St. Rank hold GTBP as of Q3 2025.

  • Front Row Advisors reported no remaining GT Biopharma position as of Q3 2025 after selling out during the quarter.
  • Front Row Advisors sold 1 GT Biopharma share in Q3 2025, an estimated $4.
  • Front Row Advisors first reported a position in GT Biopharma in Q1 2023 and held it in 8 quarters.
  • Front Row Advisors's GT Biopharma position peaked at $15 in Q4 2023.
  • 21 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2025.

Based on Front Row Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.